Journal of Medicinal Chemistry
Article
(2) (a) Maresca, A.; Temperini, C.; Vu, H.; Pham, N. B.; Poulsen, S. A.;
Scozzafava, A.; Quinn, R. J.; Supuran, C. T. Non-zinc mediated
inhibition of carbonic anhydrases: Coumarins are a new class of suicide
inhibitors. J. Am. Chem. Soc. 2009, 131, 3057−62. (b) Maresca, A.;
Temperini, C.; Pochet, L.; Masereel, B.; Scozzafava, A.; Supuran, C. T.
Deciphering the mechanism of carbonic anhydrase inhibition with
coumarins and thiocoumarins. J. Med. Chem. 2010, 53, 335−344.
(3) (a) Maresca, A.; Scozzafava, A.; Supuran, C. T. 7,8-Disubstituted-
but not 6,7-disubstituted coumarins selectively inhibit the trans-
membrane, tumor-associated carbonic anhydrase isoforms IX and XII
over the cytosolic ones I and II in the low nanomolar/subnanomolar
range. Bioorg. Med. Chem. Lett. 2010, 20, 7255−7258. (b) Touisni, N.;
Maresca, A.; McDonald, P. C.; Lou, Y.; Scozzafava, A.; Dedhar, S.;
Winum, J. Y.; Supuran, C. T. Glycosyl coumarin carbonic anhydrase IX
and XII inhibitors strongly attenuate the growth of primary breast
tumors. J. Med. Chem. 2011, 54, 8271−8277. (c) Bonneau, A.; Maresca,
A.; Winum, J. Y.; Supuran, C. T. Metronidazole-coumarin conjugates
and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic
anhydrase inhibitors. J. Enzyme Inhib. Med. Chem. 2013, 28, 397−401.
(4) Carta, F.; Maresca, A.; Scozzafava, A.; Supuran, C. T. 5- And 6-
membered (thio)lactones are prodrug type carbonic anhydrase
inhibitors. Bioorg. Med. Chem. Lett. 2012, 22, 267−270.
carbonic anhydrases I, II, IV and XII. J. Enzyme Inhib. Med. Chem. 2013,
28, 289−293. (i) Singh, S.; Supuran, C. T. QSARs on human carbonic
anhydrase VA and VB inhibitors of some new not yet synthesized,
substituted aromatic/heterocyclic sulphonamides as anti-obesity agent.
J. Enzyme Inhib. Med. Chem. 2012, 27, 666−672. (j) See more at
(9) (a) Svastova, E.; Hulíkova, A.; Rafajova, M.; Zatovicova, M.;
Gibadulinova, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C. T.;
Pastorek, J.; Pastorekova, S. Hypoxia activates the capacity of tumor-
associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett.
́
2004, 577, 439−445. (b) Thiry, A.; Dogne, J. M.; Masereel, B.; Supuran,
C. T. Targeting tumor-associated carbonic anhydrase IX in cancer
therapy. Trends Pharmacol. Sci. 2006, 27, 566−573. (c) Alterio, V.;
Hilvo, M.; Di Fiore, A.; Supuran, C. T.; Pan, P.; Parkkila, S.; Scaloni, A.;
Pastorek, J.; Pastorekova, S.; Pedone, C.; Scozzafava, A.; Monti, S. M.;
De Simone, G. Crystal structure of the catalytic domain of the tumor-
associated human carbonic anhydrase IX. Proc. Natl. Acad. Sci. U.S.A.
2009, 106, 16233−16238. (d) Ahlskog, J. K.; Schliemann, C.; Marlind,
̊
J.; Qureshi, U.; Ammar, A.; Pedleym, R. B.; Neri, D. In vivo targeting of
tumor-associated carbonic anhydrases using acetazolamide derivatives.
Bioorg. Med. Chem. Lett. 2009, 19, 4851−4856.
(5) (a) Carta, F.; Supuran, C. T.; Scozzafava, A. Sulfonamides and their
isosters as carbonic anhydrase inhibitors. Future Med. Chem. 2014, 10,
1149−1165. (b) Supuran, C. T. Carbonic anhydrases: from biomedical
applications of the inhibitors and activators to biotechnologic use for
CO2 capture. J. Enzyme Inhib. Med. Chem. 2013, 28, 229−230.
(10) (a) Stander, B. A.; Joubert, F.; Tu, C.; Sippel, K. H.; McKenna, R.;
Joubert, A. M. Signaling pathways of ESE-16, an antimitotic and
anticarbonic anhydrase estradiol analog, in breast cancer cells. PLoS One
2013, 8, e53853. (b) Pacchiano, F.; Carta, F.; McDonald, P. C.; Lou, Y.;
Vullo, D.; Scozzafava, A.; Dedhar, S.; Supuran, C. T. Ureido-substituted
benzenesulfonamides potently inhibit carbonic anhydrase IX and show
antimetastatic activity in a model of breast cancer metastasis. J. Med.
Chem. 2011, 54, 1896−1902. (c) Lou, Y.; McDonald, P. C.; Oloumi, A.;
Chia, S. K.; Ostlund, C.; Ahmadi, A.; Kyle, A.; Auf dem Keller, U.;
Leung, S.; Huntsman, D. G.; Clarke, B.; Sutherland, B. W.; Waterhouse,
D.; Bally, M. B.; Roskelley, C. D.; Overall, C. M.; Minchinton, A.;
Pacchiano, F.; Carta, F.; Scozzafava, A.; Touisni, N.; Winum, J. Y.;
Supuran, C. T.; Dedhar, S. Targeting tumor hypoxia: suppression of
breast tumor growth and metastasis by novel carbonic anhydrase IX
inhibitors. Cancer Res. 2011, 71, 3364−3376. (d) Pacchiano, F.;
Aggarwal, M.; Avvaru, B. S.; Robbins, A. H.; Scozzafava, A.; McKenna,
R.; Supuran, C. T. Selective hydrophobic pocket binding observed
within the carbonic anhydrase II active site accommodate different 4-
substituted-ureido-benzenesulfonamides and correlate to inhibitor
potency. Chem. Commun. 2010, 46, 8371−8373.
(6) (a) Alterio, V.; Di Fiore, A.; D’Ambrosio, K.; Supuran, C. T.; De
Simone, G. Multiple binding modes of inhibitors to carbonic
anhydrases: how to design specific drugs targeting 15 different isoforms?
Chem. Rev. 2012, 112, 4421−4468. (b) Supuran, C. T. Carbonic
anhydrases: novel therapeutic applications for inhibitors and activators.
Nat. Rev. Drug Discovery 2008, 7, 168−181. (c) Neri, D.; Supuran, C. T.
Interfering with pH regulation in tumours as a therapeutic strategy. Nat.
Rev. Drug Discovery 2011, 10, 767−777. (d) Aggarwal, M.; Kondeti, B.;
McKenna, R. Insights towards sulfonamide drug specificity in α-
carbonic anhydrases. Bioorg. Med. Chem. 2013, 21, 1526−1533.
(7) (a) Aggarwal, M.; McKenna, R. Update on carbonic anhydrase
inhibitors: a patent review (2008−2011). Expert. Opin. Ther. Pat. 2012,
22, 903−915. (b) Supuran, C. T. Structure-based drug discovery of
carbonic anhydrase inhibitors. J. Enzyme Inhib. Med. Chem. 2012, 27,
759−772. (c) Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic
anhydrase inhibitors. Med. Res. Rev. 2003, 23, 146−189. (d) Pastorekova,
S.; Parkkila, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrases: current
state of the art, therapeutic applications and future prospects. J. Enzyme
Inhib. Med. Chem. 2004, 19, 199−229.
(11) Carta, F.; Temperini, C.; Innocenti, A.; Scozzafava, A.; Kaila, K.;
Supuran, C. T. Polyamines inhibit carbonic anhydrases by anchoring to
the zinc-coordinated water molecule. J. Med. Chem. 2010, 53, 5511−
5522.
(8) (a) Supuran, C. T.; Scozzafava, A.; Casini, A. Development of
sulfonamide carbonic anhydrase inhibitors (CAIs). In Carbonic
AnhydraseIts Inhibitors and Activators; Supuran, C.T., Scozzafava, A.,
Conway, J., Eds.; CRC Press: Boca Raton, FL, 2004; pp 67−147.
(b) Supuran, C. T. Carbonic anhydrase inhibitors. Bioorg. Med. Chem.
Lett. 2010, 20, 3467−3474. (c) Supuran, C. T. Carbonic anhydrase
inhibitors and activators for novel therapeutic applications. Future Med.
Chem. 2011, 3, 1165−1180. (d) Aggarwal, M.; Boone, C. D.; Kondeti,
B.; McKenna, R. Structural annotation of human carbonic anhydrases. J.
Enzyme Inhib. Med. Chem. 2013, 28, 267−277. (e) Jain, A.; Whitesides,
G. M.; Alexander, R. S.; Christianson, D. W. Identification of two
hydrophobic patches in the active-site cavity of human carbonic
anhydrase II by solution-phase and solid-state studies and their use in
the development of tight-binding inhibitors. J. Med. Chem. 1994, 37,
2100−2105. (f) Allouche, F.; Chabchoub, F.; Carta, F.; Supuran, C. T.
Synthesis of aminocyanopyrazoles via a multi-component reaction and
anti-carbonic anhydrase inhibitory activity of their sulfamide derivatives
against cytosolic and transmembrane isoforms. J. Enzyme Inhib. Med.
Chem. 2013, 28, 343−349. (g) Maresca, A.; Vullo, D.; Scozzafava, A.;
Supuran, C. T. Inhibition of the alpha- and beta-carbonic anhydrases
from the gastric pathogen Helycobacter pylori with anions. J. Enzyme
Inhib. Med. Chem. 2013, 28, 388−391. (h) Supuran, C. T.; Maresca, A.;
(12) (a) Innocenti, A.; Vullo, D.; Scozzafava, A.; Supuran, C. T.
Carbonic anhydrase inhibitors: interactions of phenols with the 12
catalytically active mammalian isoforms (CA I-XIV). Bioorg. Med. Chem.
Lett. 2008, 18, 1583−1587. (b) Innocenti, A.; Vullo, D.; Scozzafava, A.;
Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of mammalian
isoforms I-XIV with a series of substituted phenols including
paracetamol and salicylic acid. Bioorg. Med. Chem. 2008, 16, 7424−
7428. (c) Davis, R. A.; Innocenti, A.; Poulsen, S. A.; Supuran, C. T.
Carbonic anhydrase inhibitors. Identification of selective inhibitors of
the human mitochondrial isozymes VA and VB over the cytosolic
isozymes I and II from a natural product-based phenolic library. Bioorg.
Med. Chem. 2010, 18, 14−18. (d) Davis, R. A.; Hofmann, A.; Osman, A.;
Hall, R. A.; Muhlschlegel, F. A.; Vullo, D.; Innocenti, A.; Supuran, C. T.;
̈
Poulsen, S. A. Natural product-based phenols as novel probes for
mycobacterial and fungal carbonic anhydrases. J. Med. Chem. 2011, 54,
1682−1692.
(13) (a) Carta, F.; Aggarwal, M.; Maresca, A.; Scozzafava, A.;
McKenna, R.; Supuran, C. T. Dithiocarbamates: a new class of carbonic
anhydrase inhibitors. Crystallographic and kinetic investigations. Chem.
Commun. 2012, 48, 1868−1870. (b) Maresca, A.; Carta, F.; Vullo, D.;
Supuran, C. T. Dithiocarbamates strongly inhibit the β-class carbonic
anhydrases from Mycobacterium tuberculosis. J. Enzyme Inhib. Med. Chem.
́ ̌
Gregan, F.; Remko, M. Three new aromatic sulfonamide inhibitors of
H
J. Med. Chem. XXXX, XXX, XXX−XXX